ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

UK Health Body Approves Novartis's Gilenya For MS

ZURICH -(Dow Jones)- The U.K.'s health-cost regulator is backing Novartis's (NVS) pill Gilenya for certain adult patients with highly active relapsing-remitting multiple sclerosis. The independent National Institute for Clinical Excellence, known by its acronym NICE, said Wednesday it is recommending Gilenya, or fingolimod, for use on the publicly funded National Health Service. "We are pleased to recommend fingolimod as a treatment option for the specific patient population for whom it has been demonstrated to be cost-effective, providing Novartis applies its proposed discount," NICE Director Carol Longson said, without disclosing the price. Gilenya has been available in the European Union since March 2011 for treating relapsing-remitting MS, the most common type of the disease. The drug was approved in the U.S. in 2010. Novartis hopes the drug will become one of the leading treatments in the multibillion-dollar market for treating MS due to its easy oral use. "Novartis welcomes this final decision from NICE, which will allow appropriate patients with highly active relapsing-remitting MS to have access to Gilenya under the NHS in England and Wales," the company said in a statement, adding that it "remains committed to engaging with reimbursement authorities with the goal of ensuring that appropriate patients will have access to the treatment." Last week, EU and US regulators requested stronger label warnings for Gilenya after conducting reviews of the pill's safety, following reports of heart problems and the death of a patient. -By Marta Falconi, Dow Jones Newswires; +41 43 443 8043; [email protected]

Stock News for Novartis (NVS)
DateTimeHeadline
03/16/201703:58:00Oxford Biomedica Loss Widens, Sees Progress in 2017
03/02/201708:16:00Novartis Fined by South Korea Over Alleged Kickbacks
02/08/201706:00:00Propeller Health Enters into Collaboration to Connect Breezhaler™ D...
01/31/201714:59:00Trump Tells Pharmaceutical CEOs He Wants Prices Down -- Update
01/26/201703:02:00Novartis Weighs Alcon Spinoff -- WSJ
01/25/201705:28:00Vectura Group Says Bronchitis Inhaler Sales Trigger Milestone...
01/25/201703:42:00Novartis May Spin Off |Alcon Eye-Care Business
01/25/201701:51:00Novartis Announces Share Buyback as Dollar Hits Earnings
01/13/201716:21:00Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech...
01/06/201713:06:00Correction to Novartis to Pay Up to $1.6 Billion to Ionis
01/06/201706:17:00Novartis to Pay Up to $1.6 Billion to Ionis, Unit for Rights...
10/27/201616:40:00Amgen Sees Profit Increase, Raises Guidance
10/25/201604:40:00Novartis Profit Helped by GlaxoSmithKline Joint Venture
10/25/201603:53:00Novartis Profit Helped by GlaxoSmithKline Joint Venture -- Update
10/25/201602:01:00Novartis Net Income Rose in 3rd Quarter
10/21/201608:14:00Novartis AG 3Q 2016 - Forecast
10/05/201608:20:00Eli Lilly to Buy Boehringer Ingelheim Pet Vaccines Portfolio
10/02/201623:40:00Novo Nordisk Bets on Riskier Insulin Research
09/23/201613:11:00Novartis receives three new FDA approvals for the expanded use...
08/30/201618:50:00FDA Approves Novartis's Biosimilar to Amgen's Enbrel

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US